$2.260
+0.149 (+6.60%)Al cierre
- Máximo
- 2.335
- Apertura
- 2.110
- Precio medio ponderado por volumen
- 2.23
- Volumen
- 133.06K
- Capitalización
- —
- Mínimo
- 2.100
- Importe
- 296.95K
- EV/EBITDA, TTM
- 0.00
Conexeu Sciences Inc. is an early-stage medical technology company. The Company is focused on developing regenerative biomaterials that address significant needs in wound care, dentistry, and aesthetics. The Company is focused on providing physicians with device-based solutions for healing, restoring soft tissue, and improving patient outcomes across multiple clinical settings. Its core device candidate, CXU, is a temperature-responsive ECM scaffold formulation intended to transition in-situ to a gel-like extra cellular matrix (ECM) within approximately minutes (Ten-Minute Tissue). The Company operates and manages its business in one operating segment, which is developing and commercializing novel cellular therapies for skin restoration in wound care and aesthetics.
Análisis de IA of Conexeu Sciences Inc (CNXU)
VenderConexeu Sciences Inc. is not a good buy right now due to its significant financial losses and poor technical indicators. The current price is $2.40, which is down 81.54% year-to-date. Additionally, the RSI is at a very low 21.385, indicating oversold conditions, but this could also suggest continued downward pressure. The company has reported a staggering net loss of $7,725,651 in Q3 2026, which raises concerns about its financial health and sustainability.
Métricas de valoración
Cronología de eventos
Noticias
8.510-15NewsfilterConexeu Closes $5 Million Private Placement for CXU™ Development
8.509-01PRnewswireGlobal Medical Aesthetics Market Poised for Significant Growth
- 8.509-01Newsfilter
Global Medical Aesthetics Market Poised for Significant Growth
- 1.009-01Newsfilter
Conexeu Sciences to Participate in Key Investor Conferences
- 8.508-18Newsfilter
Conexeu Sciences Inc. Pioneers New Regenerative Medicine Category
Preguntas frecuentes sobre CNXU, respondidas por Alphio AI
Conexeu Sciences Inc. is an early-stage medical technology company. The Company is focused on developing regenerative biomaterials that address significant needs in wound care, dentistry, and aesthetics. The Company is focused on providing physicians with device-based solutions for healing, restoring soft tissue, and improving patient outcomes across multiple clinical settings. Its core device candidate, CXU, is a temperature-responsive ECM scaffold formulation intended to transition in-situ to a gel-like extra cellular matrix (ECM) within approximately minutes (Ten-Minute Tissue). The Company operates and manages its business in one operating segment, which is developing and commercializing novel cellular therapies for skin restoration in wound care and aesthetics. It operates in the Healthcare sector.
Conexeu Sciences Inc. is not a good buy right now due to its significant financial losses and poor technical indicators. The current price is $2.40, which is down 81.54% year-to-date. Additionally, the RSI is at a very low 21.385, indicating oversold conditions, but this could also suggest continued downward pressure. The company has reported a staggering net loss of $7,725,651 in Q3 2026, which raises concerns about its financial health and sustainability.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarArtículos relacionados
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.